Source: Mediterranee Infection

COVID-IHU #15

Version 1 du 27 Mai 2020
Early diagnosis and management of COVID-19 patients: a real-life cohort study of 3,737 patients, Marseille, France

Abstract

Background:
In our institute in Marseille, France, we proposed early and massive screening for coronavirus disease 2019 (COVID-19). Hospitalization and early treatment with hydroxychloroquine and azithromycin (HCQ-AZ) was proposed for the positive cases.

Methods:
We retrospectively report the clinical management of 3,737 patients, including 3,054 (81.7%) treated with HCQ-AZ for at least three days and 683 (18.3%) patients treated with other methods (“others”). Outcomes were death, transfer to the intensive care unit (ICU), ≥ 10 days of hospitalization and viral shedding.

Results:
By testing 101,522 samples by polymerase chain reaction (PCR) from 65,993 individuals, we diagnosed 6,836 patients (10.4%), including 3,737 included in our cohort. The mean age was 45 (sd 17) years, 45% were male, and the fatality rate was 0.9%.

We performed 2,065 low-dose computed tomography (CT) scans highlighting lung lesions in 581 of the 933 (62%) patients with minimal clinical symptoms (NEWS score = 0).

A discrepancy between spontaneous dyspnoea, hypoxemia and lung lesions was observed. Clinical factors (age, comorbidities, NEWS-2 score), biological factors (lymphopenia; eosinopenia; decrease in blood zinc; and increase in D-dimers, lactate dehydrogenase (LDH), creatinine phosphokinase (CPK), and c-reactive protein (CRP)) and moderate and severe lesions detected in low-dose CT scans were associated with poor clinical outcome.

Treatment with HCQ-AZ was associated with a decreased risk of transfer to the ICU or death (HR 0.19 0.12-0.29), decreased risk of hospitalization ≥10 days (odds ratios 95% CI 0.37 0.26-0.51) and shorter duration of viral shedding (time to negative PCR: HR 1.27 1.16-1.39).

QTc prolongation (>60 ms) was observed in 25 patients (0.67%) leading to the cessation of treatment in 3 cases. No cases of torsade de pointe or sudden death were observed.

Conclusion
Early diagnosis, early isolation and early treatment with at least 3 days of HCQ-AZ result in a significantly better clinical outcome and contagiosity in patients with COVID-19 than other treatments.

Long-term follow-up to screen for fibrosis will be the next challenge in the management of COVID-19.


Related:
YALE: Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis (HCQ – AZ)


Hydroxychloroquine: Turkey continues using drug despite WHO pause


Despite WHO’s Warning, India Continues Use of Hydroxychloroquine as Prevention Measure


TANG ET AL, BMJ: Favourable data for hydroxychloroquine removed between study’s draft and final print


Hydroxychloroquine is currently being used with great success – Qatar has a case fatality rate of only 0.04% with 21 deaths out of 43,714 cases.


Hospital in Piauí heals people from covid-19 and empties ICUs with hydroxychloroquine

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

A Judge Stands up to a Hospital: “Step Aside” and Give a Dying Man Ivermectin

The judge’s finest moment may have been when he dashed the most glaring myth about ivermectin—that it is not safe, despite decades of use that shows otherwise. Noting that all drugs have side effects, Judge Fullerton listed ivermectin’s effects from a government website.
“(N)umber one, generally well tolerated; number two, dizziness; number three, pruritus; number four, nausea/diarrhea. These are the side effects for the dosage that’s being asked to be administered,” he said. “The risks of these side effects are so minimal that Mr. Ng’s current situation outweighs that risk by one-hundredfold.”

Read More »

How Dr. Paul Marik Saved a Grandmother & The World (Part 3)

Recently Merck issued a stern warning that seemed written by marketing, Kory says, “as it had no scientific data to support the conclusion,” that ivermectin was suddenly dangerous. Another pharmaceutical company’s CEO privately noted that “People must think Merck knows what they’re talking about because it’s their drug,” but Merck has “tremendous disincentives” to say nice things about the generic pill, as it has already spent hundreds of millions of dollars developing an oral anti-viral COVID-19 treatment, rival to ivermectin, that may be priced at $3,000 a dose.

Read More »

How Dr. Paul Marik Saved a Grandmother & The World (Part 2)

They also restricted the use of essential off-label and generic drugs with blatant disinformation campaigns that reminded Kory of big tobacco’s efforts to hide the dangers of smoking. In effect, the public health authorities eliminated the full toolbox of essential scientific methods and drugs that doctors use every day, including the most effective early, prophylactic, and late-stage treatments for COVID-19, which were developed by frontline doctors, not pharmaceutical companies.

Read More »

How Dr. Paul Marik Saved a Grandmother & The World (Part I)

In the professor’s continual review of “the latest (and best) literature,” he picked up a surprising “data signal” in October from emerging studies in Latin America. ivermectin, a safe, cheap, FDA-approved anti-parasitic drug, was showing remarkable anti-viral and anti-inflammatory activity as a repurposed drug—the most powerful COVID-19 killer known to science. 

Read More »